4596 — Kubota Pharmaceutical Holdings Co Income Statement
0.000.00%
- ¥3bn
- ¥1bn
- ¥27m
Annual income statement for Kubota Pharmaceutical Holdings Co, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 37.8 | 0 | 8.25 | 39.9 | 27.2 |
Cost of Revenue | |||||
Gross Profit | — | — | 2.43 | 28.1 | 22 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 2,522 | 2,585 | 2,046 | 1,544 | 1,373 |
Operating Profit | -2,484 | -2,585 | -2,038 | -1,504 | -1,345 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2,437 | -2,616 | -2,016 | -1,490 | -1,333 |
Provision for Income Taxes | |||||
Net Income After Taxes | -2,437 | -2,616 | -2,016 | -1,490 | -1,333 |
Net Income Before Extraordinary Items | |||||
Net Income | -2,437 | -2,616 | -2,016 | -1,490 | -1,333 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2,437 | -2,616 | -2,016 | -1,490 | -1,333 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -58.2 | -58.8 | -42.4 | -24.8 | -21.6 |
Dividends per Share |